Atossa Therapeutics, Inc. (ATOS) Plans CVR Paying Up To $50M From Potential PRV

Atossa approved issuing one CVR per share, entitling holders to 25% of net proceeds from monetizing its first qualifying FDA priority review voucher, capped at $50M. No product is approved and no voucher has been awarded; no CVR payment is assured.Material DetailsContext by AI AnalystThis is an ear…